These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31401686)

  • 1. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States.
    Pariser AC; Sedghi T; Soulos PR; Killelea B; Gross CP; Mougalian SS
    Breast Cancer Res Treat; 2019 Nov; 178(2):419-426. PubMed ID: 31401686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
    Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML
    Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
    Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
    Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
    Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
    JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
    Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
    Wang Y; He L; Song Y; Wu Q; Wang H; Zhang B; Ma X
    BMC Womens Health; 2020 Jan; 20(1):17. PubMed ID: 32005117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.
    Chiba A; Hoskin TL; Heins CN; Hunt KK; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 Feb; 24(2):418-424. PubMed ID: 27663568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
    van de Loo ME; Andour L; van Heesewijk AE; Oosterkamp HM; Liefers GJ; Straver ME
    Breast Cancer Res Treat; 2024 May; 205(1):5-16. PubMed ID: 38265568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
    Petruolo O; Sevilimedu V; Montagna G; Le T; Morrow M; Barrio AV
    Ann Surg Oncol; 2021 Jan; 28(1):287-294. PubMed ID: 32514804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review.
    Charehbili A; Fontein DB; Kroep JR; Liefers GJ; Mieog JS; Nortier JW; van de Velde CJ
    Cancer Treat Rev; 2014 Feb; 40(1):86-92. PubMed ID: 23891267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.
    Spronk PER; Volders JH; van den Tol P; Smorenburg CH; Vrancken Peeters MTFD
    Eur J Surg Oncol; 2019 Feb; 45(2):110-117. PubMed ID: 30348601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.
    Venigalla S; Carmona R; Guttmann DM; Jain V; Freedman GM; Clark AS; Shabason JE
    JAMA Oncol; 2018 Oct; 4(10):e181114. PubMed ID: 29800030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
    Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
    Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010-2017.
    Zhang H; Barner JC; Moczygemba LR; Rascati KL; Park C; Kodali D
    Breast Cancer Res Treat; 2022 Jun; 193(3):695-705. PubMed ID: 35449473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality impact of less-than-standard therapy in older breast cancer patients.
    Yood MU; Owusu C; Buist DS; Geiger AM; Field TS; Thwin SS; Lash TL; Prout MN; Wei F; Quinn VP; Frost FJ; Silliman RA
    J Am Coll Surg; 2008 Jan; 206(1):66-75. PubMed ID: 18155570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
    Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
    Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.
    Mougalian SS; Soulos PR; Killelea BK; Lannin DR; Abu-Khalaf MM; DiGiovanna MP; Sanft TB; Pusztai L; Gross CP; Chagpar AB
    Cancer; 2015 Aug; 121(15):2544-52. PubMed ID: 25902916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study.
    Schiza A; Fredriksson I; Sund M; Valachis A
    Breast Cancer Res Treat; 2024 Jan; 203(2):235-243. PubMed ID: 37812362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.